| Revenue growth | 27.9% YoY in FY26; Q4 grew 15.7% YoY. |
|---|---|
| Margins | FY26 EBITDA margin 34.6%; expected to return to 37-38% levels. |
| Order book | 700 metric tons initial commercial orders for battery materials. |
| Demand visibility | Strong traction in LFP value chain; 42 customers in qualification pipeline. |
| Management confidence | High, citing strategic milestones in battery materials and nutrition platforms. |
Growth
FY26 Revenue grew 27.9% to ₹642.3cr; PAT increased 25.7% to ₹174.3cr. Specialty ingredients revenue surged 62% YoY.
Outlook
Commissioning 25,000 MT Phase 1 battery materials by April 2027; targeted revenue potential ₹1,600-1,800cr at 100k MT peak capacity.
Risks
Volatile raw material prices (phosphoric acid), LPG supply disruptions, and high working capital days (213 days).
Earnings Call filed with BSE, NSE: SUDEEPPHRM. Summary written with AI assistance from the document.
Sudeep Pharma Ltd: key numbers
- Share price
- ₹1,175.00
- Market cap
- ₹13,271 Cr
- Revenue (annual)
- ₹642.3 Cr
- Net profit (annual)
- ₹172.9 Cr
- P/E (TTM)
- 72.7×Sector 47.4×
- Promoter holding
- 76.15%+0.00% QoQ
- FII holding
- 1.81%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sudeep Pharma Ltd
All →Sudeep Pharma Other Announcement
Sudeep Pharma cancelled its analyst/investor plant visit scheduled for 23–24 September 2026 due to exigencies. No financial or operational impact is indicated.
Sudeep Pharma Other Announcement
Sudeep Pharma Limited corrected a clerical error regarding the number of attendees at its Annual General Meeting, updating the count from 45 to 44.
Sudeep Pharma Investor Presentation: Key Takeaways
Sudeep Pharma reported strong Q1FY27 performance with 27% YoY revenue growth. Strategy focuses on expanding into Specialty Ingredients and high-growth Battery Materials (SAM project).
Sudeep Pharma Q1 FY27 Results: Net Profit ₹40.6 Cr, Up 29.7% YoY
Sudeep Pharma Ltd reported revenue from operations of ₹158.3 Cr (+26.7% YoY) and net profit of ₹40.6 Cr (+29.7% YoY) for Q1 FY27.
- Key figure
- Net profit ₹40.6 Cr · +29.7% YoY
Sudeep Pharma Annual General Meeting
Sudeep Pharma Limited held its 37th Annual General Meeting on August 4, 2026. The meeting transacted business including financial statement approval, director appointments, dividend declaration, and ESOP schemes.
Sudeep Pharma Capital Structure Change
Nuvama Crossover Opportunities Funds reduced their stake in Sudeep Pharma Ltd. The promoter field is 'No', indicating a non-promoter equity transaction.